[{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Whitehawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Divestment","leadProduct":"Sirolimus Protein-bound Particle","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Seladelpar Lysine","moa":"PPA-delta receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.16,"dosageForm":"Oral Capsule","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"KalVista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Spruce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KP-723","moa":"STAT6","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":1.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"bitBiome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Kaken Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $11.0 million

                          April 08, 2025

                          Lead Product(s) : Sebetralstat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Recipient : KalVista Pharmaceuticals

                          Deal Size : $22.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Through the divestment, Kaken assumes ownership of FYARRO (sirolimus protein-bound particles for injectable suspension) used to treat adults with malignant perivascular epithelioid cell tumor.

                          Product Name : Fyarro

                          Product Type : Antibiotic

                          Upfront Cash : $100.0 million

                          March 26, 2025

                          Lead Product(s) : Sirolimus Protein-bound Particle

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Whitehawk Therapeutics

                          Deal Size : $100.0 million

                          Deal Type : Divestment

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The collaboration aims to develop, manufacture and commercialize ESK-001, a highly selective, next-gen oral TYK2 inhibitor, for dermatology indications in Japan.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $40.0 million

                          March 25, 2025

                          Lead Product(s) : ESK-001

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Recipient : Alumis

                          Deal Size : $180.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723, a preclinical STAT6 inhibitor, for autoimmune and allergic diseases, including atopic dermatitis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $30.0 million

                          December 26, 2024

                          Lead Product(s) : KP-723

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Johnson & Johnson

                          Deal Size : $1,247.5 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : $14.6 million

                          November 15, 2024

                          Lead Product(s) : ND081

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Recipient : Numab Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Eisai divested its rights for Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.

                          Product Name : Merislon

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 29, 2024

                          Lead Product(s) : Betahistine Dimesilate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved FDF

                          Recipient : Eisai

                          Deal Size : $25.0 million

                          Deal Type : Divestment

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market MBX-8025 (seladelpar), a first-in-class treatment for people with primary biliary cholangitis (PBC), in Japan for PBC.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $34.0 million

                          August 01, 2023

                          Lead Product(s) : Seladelpar Lysine

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Recipient : CymaBay Therapeutics

                          Deal Size : $162.4 million

                          Deal Type : Collaboration

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 15, 2023

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Numab Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA a...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.0 million

                          May 01, 2023

                          Lead Product(s) : Tildacerfont

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Recipient : Spruce Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 29, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Recipient : bitBiome

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank